NSE - Delayed Quote INR

Piramal Pharma Limited (PPLPHARMA.NS)

Compare
226.46
-3.30
(-1.44%)
At close: February 7 at 3:30:03 PM GMT+5:30
Loading Chart for PPLPHARMA.NS
DELL
  • Previous Close 229.76
  • Open 230.40
  • Bid --
  • Ask --
  • Day's Range 224.01 - 233.00
  • 52 Week Range 114.35 - 307.90
  • Volume 2,154,398
  • Avg. Volume 6,567,622
  • Market Cap (intraday) 298.889B
  • Beta (5Y Monthly) 0.08
  • PE Ratio (TTM) 707.69
  • EPS (TTM) 0.32
  • Earnings Date --
  • Forward Dividend & Yield 0.11 (0.05%)
  • Ex-Dividend Date Jul 12, 2024
  • 1y Target Est 304.29

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

www.piramalpharma.com

6,719

Full Time Employees

March 31

Fiscal Year Ends

Recent News: PPLPHARMA.NS

View More

Performance Overview: PPLPHARMA.NS

Trailing total returns as of 2/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

PPLPHARMA.NS
14.94%
S&P BSE SENSEX
0.36%

1-Year Return

PPLPHARMA.NS
62.63%
S&P BSE SENSEX
7.91%

3-Year Return

PPLPHARMA.NS
15.95%
S&P BSE SENSEX
35.12%

5-Year Return

PPLPHARMA.NS
15.95%
S&P BSE SENSEX
89.25%

Compare To: PPLPHARMA.NS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PPLPHARMA.NS

View More

Valuation Measures

As of 2/6/2025
  • Market Cap

    303.23B

  • Enterprise Value

    346.57B

  • Trailing P/E

    696.24

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.44

  • Price/Book (mrq)

    3.84

  • Enterprise Value/Revenue

    3.90

  • Enterprise Value/EBITDA

    22.08

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.52%

  • Return on Assets (ttm)

    2.45%

  • Return on Equity (ttm)

    0.58%

  • Revenue (ttm)

    87.04B

  • Net Income Avi to Common (ttm)

    453.3M

  • Diluted EPS (ttm)

    0.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.08B

  • Total Debt/Equity (mrq)

    60.53%

  • Levered Free Cash Flow (ttm)

    -3.67B

Research Analysis: PPLPHARMA.NS

View More

People Also Watch